Following a series of tests that show harmful effects of the known anti-diabetes drug rosiglitazone and anti-obesity drug sibutramine, respective manufacturers and health agencies abroad ordered the withdrawal of these two drugs in the world-wide market.

Rosiglitazone, is an anti-diabetes drug that works as an insulin sensitizer, while sibutramine works as an anti-obesity drug. Both drugs have a reputation of having a positive effect on the patients, either as a stand alone drug, or in combination with other medications.

Although helpful, the harmful side-effects of these two drugs include increased risk of cardiovascular diseases, heart attacks and stroke. These side-effects outweigh the benefits given by rosiglitazone and sibutramine medications.
The Commission on Human Medicines, an independent committee responsible for providing expert advice on drug safety and the FDA advised the public to cease from using these two drugs and have themselves transferred to different medications.

Related terms:

• sibutramine 2011
• sibutramine in Philippine
• philippine fda sibutramine
• sibutramine withdraw philippines
• availability of sibutramine in philippines
• sibutramine philippines
• sibutramine in philippines
• sibutramine diabetes
• sibutramine 2012
• rosiglitazone withdrawal 2011
• is sibutramine withdrawn in philippines
• is sibutramine available in the philippines?
• is sibutramine available in the philippines
• drugs in philippines that are withdrawn in the market
• diabetes drug withdrawal
• c2 330ml nutrition facts
• avandia withdrawal market powerpoint
• availability of sibutramine in the philippines

Related Posts:

• No Related Posts